Agilent Technologies, Inc. $A Shares Sold by State of New Jersey Common Pension Fund D

Key Points

• The State of New Jersey Common Pension Fund D has reduced its stake in Agilent Technologies by 11.1%, selling 11,694 shares and now holding 93,334 shares valued at approximately $10.9 million.
• Agilent Technologies reported a net margin of 17.59% and a quarterly revenue of $1.67 billion, exceeding analyst expectations.
• Analysts have mixed ratings for Agilent Technologies, with six recommending a hold and eight indicating a buy, alongside a consensus target price of $139.77.

State of New Jersey Common Pension Fund D lessened its stake in Agilent Technologies, Inc. (NYSE:A - Free Report) by 11.1% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 93,334 shares of the medical research company's stock after selling 11,694 shares during the quarter. State of New Jersey Common Pension Fund D's holdings in Agilent Technologies were worth $10,918,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of A. GAMMA Investing LLC grew its holdings in shares of Agilent Technologies by 15,648.1% during the first quarter. GAMMA Investing LLC now owns 627,247 shares of the medical research company's stock worth $73,375,000 after buying an additional 623,264 shares in the last quarter. Two Sigma Investments LP grew its holdings in shares of Agilent Technologies by 345.9% during the fourth quarter. Two Sigma Investments LP now owns 769,897 shares of the medical research company's stock worth $103,428,000 after buying an additional 597,249 shares in the last quarter. Iron Triangle Partners LP purchased a new stake in shares of Agilent Technologies during the fourth quarter worth $80,110,000. Mackenzie Financial Corp grew its holdings in shares of Agilent Technologies by 141.5% during the first quarter. Mackenzie Financial Corp now owns 935,893 shares of the medical research company's stock worth $109,481,000 after buying an additional 548,344 shares in the last quarter. Finally, Northern Trust Corp grew its holdings in shares of Agilent Technologies by 12.3% during the fourth quarter. Northern Trust Corp now owns 4,192,790 shares of the medical research company's stock worth $563,259,000 after buying an additional 457,713 shares in the last quarter.

Analyst Upgrades and Downgrades

A has been the subject of a number of analyst reports. JPMorgan Chase & Co. dropped their price objective on shares of Agilent Technologies from $160.00 to $155.00 and set an "overweight" rating for the company in a report on Thursday, May 29th. Wall Street Zen raised shares of Agilent Technologies from a "hold" rating to a "buy" rating in a report on Saturday, June 28th. Barclays upped their price objective on shares of Agilent Technologies from $115.00 to $125.00 and gave the company an "equal weight" rating in a report on Tuesday, June 24th. Robert W. Baird dropped their price objective on shares of Agilent Technologies from $159.00 to $140.00 and set an "outperform" rating for the company in a report on Thursday, May 22nd. Finally, TD Cowen upped their price objective on shares of Agilent Technologies to $150.00 and gave the company a "buy" rating in a report on Thursday, May 29th. Seven investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Agilent Technologies has a consensus rating of "Moderate Buy" and a consensus target price of $139.77.

Insider Activity

In other news, CEO Padraig Mcdonnell sold 1,508 shares of the stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total transaction of $177,099.52. Following the sale, the chief executive officer owned 37,448 shares of the company's stock, valued at approximately $4,397,893.12. This represents a 3.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Agilent Technologies Trading Down 1.7%

NYSE A traded down $2.0330 during trading hours on Thursday, reaching $117.0770. The company had a trading volume of 736,254 shares, compared to its average volume of 1,948,706. The stock has a 50-day moving average of $117.83 and a 200 day moving average of $117.87. Agilent Technologies, Inc. has a 1-year low of $96.43 and a 1-year high of $153.84. The company has a current ratio of 2.09, a quick ratio of 1.60 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $33.26 billion, a P/E ratio of 28.91, a price-to-earnings-growth ratio of 3.64 and a beta of 1.22.

Agilent Technologies (NYSE:A - Get Free Report) last posted its earnings results on Wednesday, May 28th. The medical research company reported $1.31 EPS for the quarter, beating analysts' consensus estimates of $1.26 by $0.05. Agilent Technologies had a net margin of 17.59% and a return on equity of 25.92%. The company had revenue of $1.67 billion for the quarter, compared to analysts' expectations of $1.63 billion. During the same quarter in the prior year, the company posted $1.22 earnings per share. Agilent Technologies's revenue for the quarter was up 6.0% compared to the same quarter last year. Agilent Technologies has set its FY 2025 guidance at 5.540-5.610 EPS. Q3 2025 guidance at 1.350-1.370 EPS. As a group, research analysts anticipate that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.